FAILReviewer 1· 70% conf
The paper does not report key design elements expected for a computational study, such as dataset selection rationale, data curation criteria, or baseline controls.
Evidence
absence[Materials and methods, section 2.2-2.4]
No dataset selection rationale or power analysis is provided.absence[Materials and methods, section 2.4]
No inclusion/exclusion criteria for the drug analogs are specified.absence[Materials and methods]
No baseline or control computational experiment (e.g., non-fluorinated analogs) is described.PASSReviewer 2· 90% conf
The computational study design is adequate: key resources are identified, methods for docking and simulation are described, and controls (e.g., re-docking) are reported.
Evidence
direct quote[Materials and methods, section 2.5]
“To improve the accuracy of our outcomes, we operated verify tests, including a re-docking evaluation, utilizing the 1-Click Docking server for molecular docking.”direct quote[Results, section 3.3]
“These drug molecules were chosen on the basis of lower molecular weight.”paraphrase[Materials and methods, sections 2.5 and 2.7]
“1-Click docking, admetSAR, SwissADME, CLC-Pred, Blast2GO, Mega11, Desmond (Schrödinger), and Biovia Discovery Studio are named.”WARNReviewer 3· 75% conf
The study employs standard in silico docking and MD protocols, but several design sub-criteria are not reported or are incomplete, including power analysis, replicate distinction, inclusion/exclusion criteria for ligands, and outlier handling.
Evidence
direct quote[Results, section 3.3]
“These drug molecules were chosen on the basis of lower molecular weight.”absence[Methods, section 2.5]
No negative control or positive comparator docking is described.absence[Results, section 3.4]
No independent replication of docking or MD results is reported.